Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type. natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.

Anker, S., Butler, J., Filippatos, G., Shahzeb Khan, M., Ferreira, J., Bocchi, E., et al. (2020). Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. EUROPEAN JOURNAL OF HEART FAILURE, 22(12), 2383-2392 [10.1002/ejhf.2064].

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

Senni M;
2020

Abstract

Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type. natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
Articolo in rivista - Articolo scientifico
Empagliflozin; Heart failure with preserved ejection fraction; Sodium–glucose co-transporter 2 inhibitors;
English
2383
2392
10
Anker, S., Butler, J., Filippatos, G., Shahzeb Khan, M., Ferreira, J., Bocchi, E., et al. (2020). Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. EUROPEAN JOURNAL OF HEART FAILURE, 22(12), 2383-2392 [10.1002/ejhf.2064].
Anker, S; Butler, J; Filippatos, G; Shahzeb Khan, M; Ferreira, J; Bocchi, E; Böhm, M; Brunner-La Rocca, H; Choi, D; Chopra, V; Chuquiure, E; Giannetti, N; Gomez-Mesa, J; Janssens, S; Januzzi, J; Gonzalez-Juanatey, J; Merkely, B; Nicholls, S; Perrone, S; Piña, I; Ponikowski, P; Senni, M; Seronde, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zhang, J; Jamal, W; Schnaidt, S; Schnee, J; Brueckmann, M; Pocock, S; Zannad, F; Packer, M; EMPEROR-Preserved Trial Committees and, I
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/372869
Citazioni
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 48
Social impact